Last reviewed · How we verify
NCT05052333
Examine the Psychosocial Impacts of COVID-19 Pandemic.
trial in Psychosocial Impacts in 2,574 participants. Completed in 31 October 2023.
30 September 2023
Quick facts
| Lead sponsor | University of Otago |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,574 |
| Start date | 1 December 2021 |
| Primary completion | 30 September 2023 |
| Estimated completion | 31 October 2023 |
| Sites | 9 locations across Pakistan, Iraq, Malaysia, Indonesia, Iran, Turkey (Türkiye), United States |
Conditions studied
- Psychosocial Impacts — all drugs for Psychosocial Impacts →
- COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
Sponsor
University of Otago
Who can join
18 and older, any sex, with Psychosocial Impacts or COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study examining the psychosocial impacts of the COVID-19 pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia, Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of wellbeing (WHO Well-Being Index), psychological distress (Kessler 10), post-traumatic stress (PTSD Checklist for DSM-5), post-traumatic growth (Posttraumatic Growth Inventory), and a novel pandemic-related stress (COVID Psychosocial Impacts Scale). Data was collected employing either a unilingual (in native language) or bilingual online survey (with English as a second language) from participants (N=2574) aged 18 and above using a non-probability convenient sampling. The findings enabled us to examine the psychosocial impacts of COVID-19, validate the translations of the CPIS and standardized measures; and determine the trajectory of study variables with pandemic exposure.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The COVID Psychosocial Impacts Scale: A Reliable and Valid Tool to Examine the Psychosocial Impacts of the COVID-19 Pandemic.
Tanveer S, Schluter PJ, Beaglehole B, Porter RJ, et al · · 2023 · cited 4× · PMID 37297593 · DOI 10.3390/ijerph20115990 -
Examining the psychosocial impacts of the COVID-19 pandemic: an international cross-sectional study protocol.
Tanveer S, Schluter PJ, Porter RJ, Boden J, et al · · 2023 · cited 3× · PMID 37045574 · DOI 10.1136/bmjopen-2022-067886
Verify or expand the search:
- PubMed search for NCT05052333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Otago trials
Trials by the same sponsor.
- NCT05030909 — Feasibility Study of a Group Intervention for Youth Wellbeing · NA · recruiting
- NCT05581797 — Psilocybin-assisted Interpersonal Therapy for Depression · NA · completed
- NCT05576259 — oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder · NA · completed
- NCT05090046 — Understanding Neurocognitive Impairment After Trauma Exposure · completed
- NCT04909177 — oVRcome Self-guided Virtual Reality for Specific Phobias · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05052333 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Otago
- Last refreshed: 6 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05052333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing